The ovarian cancers are characterized by reduced SMARCA4 gene expression and/or reduced protein function and, consequently, they are sensitive to growth and/or survival inhibition by one or more compounds that restore SMARCA4 gene expression and/or protein function. This evidence concerns the gene SMARCA4 and ovarian carcinoma.